Hegelei Pharmaceutical Constructs Plant In Dalian
This article was originally published in PharmAsia News
Executive Summary
Hegelei Dalian Pharmaceutical recently commenced construction on its RMB 803 million ($117 million) project on Dalian's Changxing island. On a site measuring 200,000 square meters, the company will finish the first phase of construction on its plant this October, complete manufacturing facilities installation and testing this December, and go into operation by end of the year. Hegelei has signed a letter of intent with German firm Maxi, a large pharmaceutical business distributing medium- and high-end anti-tumor drugs. The companies will jointly establish the largest clinical research outsourcing base in Liaoning. In addition, Hegelei will act as an agent for Maxi to bring the latter's anti-tumor drugs into China. (Click here for more - Chinese Language)